Editorial: Response assessment of radioligand therapies.
作者信息
Lopci Egesta, Prasad Vikas
机构信息
Nuclear Medicine, IRCCS Humanitas Research Hospital, Rozzano (MI), Italy.
Department of Nuclear Medicine, University Hospital Ulm, Ulm, Germany.
出版信息
Front Oncol. 2022 Jul 27;12:904337. doi: 10.3389/fonc.2022.904337. eCollection 2022.
Abstract
摘要
相似文献
1
Editorial: Response assessment of radioligand therapies.社论：放射性配体疗法的疗效评估
Front Oncol. 2022 Jul 27;12:904337. doi: 10.3389/fonc.2022.904337. eCollection 2022.
2
Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients.镥-177标记的前列腺特异性膜抗原对多线治疗后转移性去势抵抗性前列腺癌进行姑息性放射性配体治疗的疗效和血液学毒性
Diagnostics (Basel). 2021 Mar 14;11(3):515. doi: 10.3390/diagnostics11030515.
3
Response assessment using Ga-PSMA ligand PET in patients undergoing Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.应用 Ga-PSMA 配体 PET 对接受 Lu-PSMA 放射性配体治疗的转移性去势抵抗性前列腺癌患者进行疗效评估。
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072. doi: 10.1007/s00259-018-4236-4. Epub 2018 Dec 19.
4
Case Report: 18F-PSMA PET/CT Scan in Castration Resistant Prostate Cancer With Aggressive Neuroendocrine Differentiation.病例报告：18F-PSMA PET/CT扫描在具有侵袭性神经内分泌分化的去势抵抗性前列腺癌中的应用
Front Oncol. 2022 Jul 22;12:937713. doi: 10.3389/fonc.2022.937713. eCollection 2022.
5
Target Heterogeneity in Oncology: The Best Predictor for Differential Response to Radioligand Therapy in Neuroendocrine Tumors and Prostate Cancer.肿瘤学中的靶点异质性：神经内分泌肿瘤和前列腺癌对放射性配体治疗差异反应的最佳预测指标
Cancers (Basel). 2021 Jul 19;13(14):3607. doi: 10.3390/cancers13143607.
6
Real-World Data Analysis of Efficacy and Survival After Lutetium-177 Labelled PSMA Ligand Therapy in Metastatic Castration-Resistant Prostate Cancer.镥-177 标记 PSMA 配体治疗转移性去势抵抗性前列腺癌的疗效和生存的真实世界数据分析。
Target Oncol. 2021 May;16(3):369-380. doi: 10.1007/s11523-021-00801-w. Epub 2021 Mar 9.
7
In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2 Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With Lu-PSMA.与前列腺特异性抗原（PSA）相比，基于改良实体瘤疗效评价标准（RECIST）1.1在2个周期后进行的中期镓-68-前列腺特异性膜抗原（PSMA）正电子发射断层扫描（PET）/计算机断层扫描（CT）反应评估，能更好地预测接受镥-PSMA治疗的前列腺癌患者的总生存期。
Front Oncol. 2021 Mar 17;11:578093. doi: 10.3389/fonc.2021.578093. eCollection 2021.
8
Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer.镥-PSMA-617放射性配体疗法治疗一名淋巴结转移性前列腺癌患者。
Oncotarget. 2017 Aug 2;8(39):66112-66116. doi: 10.18632/oncotarget.19805. eCollection 2017 Sep 12.
9
Ga-PSMA PET/CT for monitoring response to Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.镓-PSMA PET/CT 用于监测转移性去势抵抗性前列腺癌患者对 Lu-PSMA-617 放射性配体治疗的反应。
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1054-1062. doi: 10.1007/s00259-019-4258-6. Epub 2019 Jan 29.
10
Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.前列腺腺癌伴神经内分泌分化：18F-FDG PET/CT 和 68Ga-DOTANOC PET/CT 相对于 68Ga-PSMA PET/CT 的潜在效用。
Clin Nucl Med. 2018 Apr;43(4):248-249. doi: 10.1097/RLU.0000000000002013.
引用本文的文献
1
DNA Damage Repair Defects and Targeted Radionuclide Therapies for Prostate Cancer: Does Mutation Really Matter? A Systematic Review.DNA损伤修复缺陷与前列腺癌的靶向放射性核素治疗：突变真的重要吗？一项系统综述
Life (Basel). 2022 Dec 24;13(1):55. doi: 10.3390/life13010055.
本文引用的文献
1
Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial.Lu-Dotatate 联合长效奥曲肽与高剂量长效奥曲肽治疗肠神经内分泌肿瘤患者（NETTER-1）：一项开放标签、随机、对照、III 期临床试验的最终总生存和长期安全性结果。
Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6. Epub 2021 Nov 15.
2
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.镥 177-PSMA-617 治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
3
[Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.[吕]Lu-PSMA-617 对比卡巴他赛用于转移性去势抵抗性前列腺癌（TheraP）患者：一项随机、开放标签、2 期试验。
Lancet. 2021 Feb 27;397(10276):797-804. doi: 10.1016/S0140-6736(21)00237-3. Epub 2021 Feb 11.
4
Phase 3 Trial of Lu-Dotatate for Midgut Neuroendocrine Tumors.镥[177Lu]奥曲肽治疗中肠神经内分泌肿瘤的3期试验
N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427.
5
mTOR signaling in growth control and disease.mTOR 信号在生长控制和疾病中的作用。
Cell. 2012 Apr 13;149(2):274-93. doi: 10.1016/j.cell.2012.03.017.
6
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).实体瘤新的疗效评价标准：修订的RECIST指南（第1.1版）
Eur J Cancer. 2009 Jan;45(2):228-47. doi: 10.1016/j.ejca.2008.10.026.
7
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.实体瘤治疗反应评估新指南。欧洲癌症研究与治疗组织、美国国立癌症研究所、加拿大国立癌症研究所。
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16. doi: 10.1093/jnci/92.3.205.
Zotero 插件